[KongchangAI]
Unverified85% confidenceDecision RuleTime unknown

可定为阿斯利康原研产品,通过一致性评价的国产仿制品在疗效上被认为等效,选择原研还是仿制主要取决于医保报销政策和个人对品牌的信赖程度

1
Sources
85%
Confidence
Long-term
Relevance
-
First Seen

Sources

Related Entities

Related Claims

Cite This Claim

Stable URI
https://kongchang.com/claim/776830
API
curl https://kongchang.com/api/v1/knowledge/claims/776830
MCP
get_claim(id=776830)